GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Fingolimod Hydrochloride

Company
General Hospital of Shenyang Military Region
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Fingolimod Hydrochloride and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04480853

    Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 30 participants Est. completion 2027-09-30 6 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT05307731

    Fingolimod for Type 2 Diabetes Mellitus

    Not yet reported General Hospital of Shenyang Military Region 40 participants Est. completion 2028-03-15 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT05962177

    Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

    Not yet reported University Hospital, Montpellier 400 participants Est. completion 2030-06 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT06408259

    Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

    Not yet reported Bristol-Myers Squibb 194 participants Est. completion 2036-07-13 33 sites
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Recruiting NCT NCT06424067

    Phase 2 Study of Fingolimod in Lung Cancers

    Not yet reported Medical University of South Carolina 38 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Small-cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT07220252

    Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

    Not yet reported, Not yet reported TG Therapeutics, Inc. 240 participants Est. completion 2033-06-30 2 sites Stand-alone
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00098735

    Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

    Not yet reported Novartis Pharmaceuticals 140 participants
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00099736

    Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

    Not yet reported Novartis Pharmaceuticals 696 participants Est. completion 2005-09-19 42 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00099749

    Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

    Not yet reported, Not yet reported Novartis Pharmaceuticals 255 participants 5 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00099801

    Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

    Not yet reported Novartis Pharmaceuticals Est. completion 2006-03
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00239785

    Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 684 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00239798

    Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 255 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00239811

    Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 684 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00239863

    Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 684 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00239876

    Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 140 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00239902

    Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

    Not yet reported Novartis Pharmaceuticals 396 participants
    Other conditions: Renal Transplantation
    View official trial listing →
  • Completed NCT NCT00273364

    Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

    Not yet reported Northwestern University 110 participants Est. completion 2019-08-30 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00289978

    Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis 1272 participants Est. completion 2009-07 115 sites Stand-alone
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00333138

    Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

    Not yet reported Novartis 281 participants Est. completion 2011-04 26 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00340834

    Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

    Not yet reported Novartis 1292 participants Est. completion 2011-07 170 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00355134

    Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis 1083 participants Est. completion 2011-08 112 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00416845

    Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

    Not yet reported Novartis 39 participants 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00537082

    Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

    Not yet reported Novartis 171 participants 18 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00662649

    Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis 920 participants Est. completion 2011-06 103 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00670449

    An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis

    Not yet reported Novartis 143 participants Est. completion 2012-04 20 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00731523

    Pharmacokinetics (PK) and Metabolism of FTY720 in Patients With Severe Renal Impairment and Healthy Matched Subjects.

    Not yet reported Novartis 18 participants 1 site Stand-alone
    Other conditions: Renal Insufficiency
    View official trial listing →
  • Terminated NCT NCT00731692

    This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

    Not yet reported Novartis Pharmaceuticals 970 participants Est. completion 2015-06-22 157 sites Stand-alone
    Other conditions: Primary Progressive Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT00785083

    A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

    Not yet reported Novartis 36 participants 1 site
    Other conditions: Asthma
    View official trial listing →
  • Completed NCT NCT01127750

    Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

    Not yet reported Novartis 2417 participants Est. completion 2011-10 289 sites
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01199861

    Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

    Not yet reported Novartis 138 participants Est. completion 2011-05 25 sites Stand-alone
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01201356

    Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 4125 participants Est. completion 2018-10-19 458 sites Stand-alone
    Other conditions: Relapsing Forms of Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01216072

    A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 1053 participants Est. completion 2012-08 149 sites Stand-alone
    Other conditions: Relapsing Forms of Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01281657

    Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program

    Novartis 64 participants Est. completion 2012-07 58 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01285479

    The Gilenya Pregnancy Registry

    Novartis Pharmaceuticals 312 participants Est. completion 2024-05-29 61 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01310166

    Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 447 participants Est. completion 2012-07 61 sites Stand-alone
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01317004

    Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change

    Not yet reported Novartis Pharmaceuticals 61 participants Est. completion 2014-06 17 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01333501

    Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

    Not yet reported Novartis Pharmaceuticals 151 participants Est. completion 2015-09 26 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01420055

    Fingolimod -Response According to Coping - Evaluation

    Not yet reported Novartis Pharmaceuticals 189 participants Est. completion 2013-06 47 sites Stand-alone
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Terminated NCT NCT01436643

    Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression

    Not yet reported Novartis Pharmaceuticals 54 participants Est. completion 2013-09 25 sites Stand-alone
    Other conditions: Depression, Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01442194

    Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

    Novartis Pharmaceuticals 3076 participants Est. completion 2020-07-10 238 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT01490840

    Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 178 participants Est. completion 2014-07 32 sites Stand-alone
    Other conditions: Fatigue in Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01497262

    Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 162 participants Est. completion 2014-04 29 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01498887

    Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

    Not yet reported Novartis Pharmaceuticals 347 participants Est. completion 2015-12-26 47 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT01499667

    Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

    Not yet reported Novartis Pharmaceuticals 142 participants Est. completion 2012-11 44 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
    View official trial listing →
  • Completed NCT NCT01534182

    Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)

    Not yet reported Novartis Pharmaceuticals 298 participants Est. completion 2013-06 26 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01578330

    A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

    Not yet reported Novartis Pharmaceuticals 42 participants Est. completion 2015-04 11 sites Stand-alone
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Completed NCT NCT01585298

    STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

    Not yet reported Novartis Pharmaceuticals 6998 participants Est. completion 2016-12-12 258 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01592097

    Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

    University of Southern California 51 participants Est. completion 2018-04 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT01621269

    ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon

    Not yet reported Novartis Pharmaceuticals Est. completion 2014-06 Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01623596

    Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

    Not yet reported Novartis Pharmaceuticals 881 participants Est. completion 2015-07-13 123 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01625182

    Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

    Not yet reported Novartis Pharmaceuticals 106 participants Est. completion 2016-09-03 67 sites Stand-alone
    Other conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    View official trial listing →
  • Terminated NCT NCT01633112

    MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

    Not yet reported Novartis Pharmaceuticals 1064 participants Est. completion 2018-04-30 130 sites Stand-alone
    Other conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
    View official trial listing →
  • Terminated NCT NCT01647880

    MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)

    Not yet reported, Not yet reported Charite University, Berlin, Germany 15 participants Est. completion 2016-04 2 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01704183

    Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis

    Kuopio University Hospital 27 participants Est. completion 2014-03 2 sites
    Other conditions: Relapse-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT01705236

    A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

    Not yet reported Novartis Pharmaceuticals 87 participants Est. completion 2019-02-18 10 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis RRMS
    View official trial listing →
  • Withdrawn NCT NCT01709812

    Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS

    Not yet reported Novartis Pharmaceuticals Est. completion 2013-07
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT01755871

    Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

    Not yet reported Heinrich-Heine University, Duesseldorf 8 participants Est. completion 2016-02 1 site Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT01757691

    Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

    Not yet reported Novartis Pharmaceuticals 2 participants Est. completion 2014-05 2 sites Stand-alone
    Other conditions: Acute Demylelinating Optic Neuritis
    View official trial listing →
  • Completed NCT NCT01779700

    Fingolimod in Schizophrenia Patients

    Not yet reported Indiana University 40 participants Est. completion 2016-08 3 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01786174

    Gilenya in Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Massachusetts General Hospital 30 participants Est. completion 2015-05 4 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Terminated NCT NCT01790269

    Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod

    Charite University, Berlin, Germany 21 participants Est. completion 2018-08 1 site
    Other conditions: Relapsing-Remitting Multiple Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT01791192

    Study of FTY720 in Patients With Uveitis

    Not yet reported Novartis Pharmaceuticals Est. completion 2014-10 Stand-alone
    Other conditions: Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
    View official trial listing →
  • Status unknown NCT NCT01811290

    A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

    Simnad, Virginia, M.D. 36 participants Est. completion 2018-12 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT01892722

    Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 240 participants Est. completion 2030-02-18 73 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT01941004

    Safety and Efficacy of Fingolimod in MS Patients in China

    Not yet reported Novartis Pharmaceuticals Est. completion 2017-05 Stand-alone
    Other conditions: Multiple Sclerosis (Relapsing Remitting)
    View official trial listing →
  • Completed NCT NCT01981161

    Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis

    University Hospital, Toulouse 307 participants Est. completion 2018-11-30 12 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02002390

    Efficacy and Safety of FTY720 for Acute Stroke

    Not yet reported Tianjin Medical University General Hospital 22 participants Est. completion 2014-10-01 1 site Stand-alone
    Cardiovascular disease Other conditions: Vascular Accident, Ischemic Cerebrovascular Accident
    View official trial listing →
  • Completed NCT NCT02021162

    Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis

    University at Buffalo 50 participants Est. completion 2018-10 1 site
    Other conditions: Multiple Sclerosis, Healthy
    View official trial listing →
  • Completed NCT NCT02048072

    Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS

    Not yet reported Jochen Vehoff 33 participants Est. completion 2015-06 1 site
    Other conditions: Multiple Sclerosis, Autonomic Nervous System Dysfunction
    View official trial listing →
  • Completed NCT NCT02061137

    Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome

    Not yet reported, Not yet reported University Hospital, Basel, Switzerland 6 participants Est. completion 2018-04 1 site Stand-alone
    Other conditions: Rett's Syndrome
    View official trial listing →
  • Completed NCT NCT02137707

    Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

    McGill University 135 participants Est. completion 2018-10-30 6 sites
    Other conditions: Multiple Sclerosis-Relapsing-Remitting
    View official trial listing →
  • Completed NCT NCT02139696

    Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation

    Turku University Hospital 10 participants Est. completion 2016-10 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02141022

    Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya

    Not yet reported Stony Brook University 20 participants Est. completion 2015-09 1 site
    Other conditions: Multiple Sclerosis, Cognitive Deficits, Gilenya Modifying Therapy for MS
    View official trial listing →
  • Completed NCT NCT02193217

    A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303

    Not yet reported Tanabe Pharma Corporation 81 participants Est. completion 2015-01 1 site
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02225977

    Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.

    University of Southern California 125 participants Est. completion 2017-04-30 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02232061

    Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks

    Not yet reported Novartis Pharmaceuticals 6 participants Est. completion 2020-01-24 4 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT02241785

    Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

    Not yet reported Biogen 47 participants Est. completion 2016-05-02 11 sites
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02277964

    Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

    University Hospital, Basel, Switzerland 25 participants Est. completion 2016-08 1 site
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02307838

    Long-term Follow-up of Fingolimod Phase II Study Patients

    Not yet reported Novartis Pharmaceuticals 177 participants Est. completion 2015-12 26 sites
    Other conditions: Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02307877

    Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

    University of Colorado, Denver 157 participants Est. completion 2018-05 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT02325440

    Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya

    Not yet reported University Hospital Muenster 15 participants Est. completion 2016-04 1 site Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02335892

    PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

    Novartis Pharmaceuticals 114 participants Est. completion 2017-02-01 14 sites
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT02342704

    Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

    Not yet reported Biogen 111 participants Est. completion 2016-05-18 42 sites
    Other conditions: Relapsing-Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02373098

    Fingolimod Effect on Cytokine and Chemokine Levels

    Not yet reported Novartis Pharmaceuticals 126 participants Est. completion 2017-01-18 3 sites Stand-alone
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT02408380

    Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)

    McGill University 216 participants Est. completion 2015-12 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02490930

    A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5 participants Est. completion 2017-09 1 site Stand-alone
    Other conditions: Glioblastoma, Anaplastic Astrocytoma
    View official trial listing →
  • Terminated NCT NCT02575365

    Effect of Fingolimod on Neurodegeneration

    Not yet reported Novartis Pharmaceuticals 4 participants Est. completion 2017-01-27 3 sites Stand-alone
    Other conditions: Cognition, Brain Volume Loss
    View official trial listing →
  • Completed NCT NCT02720107

    Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

    Not yet reported Novartis Pharmaceuticals 133 participants Est. completion 2016-11-14 26 sites Stand-alone
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT02769689

    Methylprednisolone During the Switch Between Natalizumab and Fingolimod

    Not yet reported University Hospital, Clermont-Ferrand 56 participants Est. completion 2024-07-20 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02776072

    Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

    Biogen 2978 participants Est. completion 2016-12 121 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02799199

    Fingolimod Real World Experience: the French Grand-Est Cohort

    CHU de Reims 1014 participants Est. completion 2015-10
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT02939079

    Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

    Not yet reported, Not yet reported Isfahan University of Medical Sciences 50 participants Est. completion 2016-10 Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Withdrawn NCT NCT02956200

    Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine Est. completion 2018-12 1 site Stand-alone
    Cardiovascular disease Other conditions: Inflammation
    View official trial listing →
  • Completed NCT NCT03193866

    COMparison Between All immunoTherapies for Multiple Sclerosis.

    Karolinska Institutet 3526 participants Est. completion 2022-03-31 1 site
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT03216915

    Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis

    Universitätsklinikum Hamburg-Eppendorf 100 participants Est. completion 2020-12-31 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT03243721

    Gilenya's Impact on Cognitive Function and Thalamic Volumes

    Not yet reported The Cleveland Clinic 20 participants Est. completion 2019-11-12 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT03257358

    A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

    Not yet reported Novartis Pharmaceuticals 382 participants Est. completion 2019-06-28 66 sites
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Terminated NCT NCT03345940

    Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis

    Not yet reported Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 55 participants Est. completion 2019-10-30 1 site
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT03399981

    Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries

    Biogen 80327 participants Est. completion 2023-12-31 1 site
    Other conditions: Progressive Multifocal Leukoencephalopathy
    View official trial listing →
  • Active, not recruiting NCT NCT03500328

    Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

    Not yet reported Johns Hopkins University 900 participants Est. completion 2026-09 47 sites
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Active, not recruiting NCT NCT03535298

    Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

    Not yet reported The Cleveland Clinic 800 participants Est. completion 2027-07-30 30 sites
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Completed NCT NCT03623243

    Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

    Not yet reported Novartis Pharmaceuticals 185 participants Est. completion 2022-07-06 55 sites Stand-alone
    Other conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT03757338

    Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod

    Not yet reported Asofarma S.A.I. y C. 33 participants Est. completion 2016-01-26 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03941743

    Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

    Not yet reported Mayo Clinic 2 participants Est. completion 2021-11-23 3 sites Stand-alone
    Other conditions: Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT03943498

    Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy

    Not yet reported Mayo Clinic 2 participants Est. completion 2020-12-10 2 sites Stand-alone
    Other conditions: Chemotherapy-Induced Peripheral Neuropathy, Numbness, Pain, Tingling
    View official trial listing →
  • Completed NCT NCT04088630

    Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

    Not yet reported Wake Forest University Health Sciences 28 participants Est. completion 2024-06-05 1 site Stand-alone
    Cardiovascular disease Other conditions: Intracerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
    View official trial listing →
  • Withdrawn NCT NCT04280588

    Fingolimod in COVID-19

    Not yet reported First Affiliated Hospital of Fujian Medical University Est. completion 2020-07-01 1 site Stand-alone
    Other conditions: Coronavirus Disease (COVID-19)
    View official trial listing →
  • Completed NCT NCT04353492

    An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

    Not yet reported Novartis Pharmaceuticals 562 participants Est. completion 2025-03-11 123 sites
    Other conditions: Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT04472975

    Prescription Drug Safety and Effectiveness in Multiple Sclerosis

    University of British Columbia 35000 participants Est. completion 2018-03-31
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT04629872

    Fingolimod in Endovascular Treatment of Ischemic Stroke

    Not yet reported Ning Wang, MD., PhD. 30 participants Est. completion 2023-12-30 1 site Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT04657744

    Bioequivalence Study of Fingolimod From Sphingomod 0.5 mg Hard Gelatin Capsules (Hikma Pharma, Egypt) Versus Gilenya 0.5 mg Hard Capsules (Novartis Pharma AG, Basle, Switzerland).

    Not yet reported Genuine Research Center, Egypt 34 participants Est. completion 2020-10-20 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04667949

    Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

    Not yet reported Novartis Pharmaceuticals 98 participants Est. completion 2025-03-25 13 sites Stand-alone
    Other conditions: Relapsing Multiple Sclerosis (RMS)
    View official trial listing →
  • Status unknown NCT NCT04675762

    Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 118 participants Est. completion 2026-03-15 1 site Stand-alone
    Cardiovascular disease Other conditions: Inflammation
    View official trial listing →
  • Status unknown NCT NCT04676204

    Relationship Between Oral DMT Burden and Adherence in MS

    Monash University 323 participants Est. completion 2026-07-11 1 site
    Other conditions: Multiple Sclerosis, Adherence, Medication
    View official trial listing →
  • Status unknown NCT NCT04718064

    Revascularization Pretreated With Fingolimod in Acute Stroke

    Not yet reported The Affiliated Hospital of Xuzhou Medical University 20 participants Est. completion 2022-01-31 Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT04796584

    Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

    Providence Health & Services 20 participants Est. completion 2022-10-25 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT04821596

    Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis

    Not yet reported University Hospital, Rouen 77 participants Est. completion 2021-12-14 1 site Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT04926818

    Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

    Not yet reported Novartis Pharmaceuticals 129 participants Est. completion 2031-02-28 51 sites
    Other conditions: Multiple Sclerosis (MS)
    View official trial listing →
  • Completed NCT NCT05060354

    COVID-19 Vaccine Response in Treated MS Patients

    Brigham and Women's Hospital 159 participants Est. completion 2023-09-28 1 site
    Other conditions: Multiple Sclerosis, Healthy
    View official trial listing →
  • Status unknown NCT NCT05112484

    Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Sclerosis

    University Hospital Ostrava 600 participants Est. completion 2026-05 2 sites
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Active, not recruiting NCT NCT05123703

    A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

    Not yet reported Hoffmann-La Roche 188 participants Est. completion 2029-09-17 71 sites Stand-alone
    Other conditions: Relapsing-remitting Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05141669

    Impact of Fingolimod Adherence on Outcomes

    Novartis Pharmaceuticals 694 participants Est. completion 2020-11-20 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05145621

    Oral Bio-equivalence Study

    Not yet reported Alembic Pharmaceuticals Ltd. 26 participants Est. completion 2016-01-15 1 site
    Other conditions: Bioequivalence, Safety
    View official trial listing →
  • Active, not recruiting NCT NCT05269888

    Covid-19 Vaccine Immune Response in Multiple Sclerosis

    University Hospitals of North Midlands NHS Trust 240 participants Est. completion 2025-12-30 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Enrolling by invitation NCT NCT05285878

    Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

    Not yet reported The Methodist Hospital Research Institute 20 participants Est. completion 2027-12 1 site
    Other conditions: Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
    View official trial listing →
  • Not yet recruiting NCT NCT05415579

    Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)

    Dongzhimen Hospital, Beijing 2000 participants Est. completion 2030-05-31
    Other conditions: Demyelinating Diseases of the Central Nervous System (DDC)
    View official trial listing →
  • Completed NCT NCT05423769

    Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

    Hikma Pharmaceuticals LLC 30 participants Est. completion 2023-11-30 2 sites
    Other conditions: Relapsing-Remitting Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT05516303

    Pharmacogenetics of Liver Toxicity in Patients With Multiple Sclerosis Treated With Fingolimod

    University Hospital, Caen 65 participants Est. completion 2022-10-31 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05528666

    Risk Perception in Multiple Sclerosis

    Novartis Pharmaceuticals 4361 participants Est. completion 2021-09-17 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05684016

    Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

    Not yet reported George Washington University 75 participants Est. completion 2016-12 1 site
    Other conditions: Multiple Sclerosis, Relapsing-Remitting
    View official trial listing →
  • Active, not recruiting NCT NCT05688436

    A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

    Biogen 1178 participants Est. completion 2031-01-17 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05718947

    Ultra-high-field Brain MRI in Multiple Sclerosis

    Zuyderland Medisch Centrum 10 participants Est. completion 2024-06-17 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT05762003

    Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

    IMPULS Endowment Fund 17478 participants Est. completion 2021-12-31 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT06087965

    Fingolimod in Minimal Invasive Treatment of Intracerebral Hemorrhage

    Not yet reported, Not yet reported Tang-Du Hospital 40 participants Est. completion 2025-12-30 Stand-alone
    Other conditions: Intracerebral Hemorrhage
    View official trial listing →
  • Completed NCT NCT06705608

    Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study

    University of British Columbia 4000 participants Est. completion 2020-12-31
    Other conditions: Multiple Sclerosis, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell, Multiple Sclerosis (MS) - Relapsing-remitting
    View official trial listing →
  • Not yet recruiting NCT NCT06949956

    Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

    Elpen Pharmaceutical Co. Inc. 140 participants Est. completion 2027-12-31
    Other conditions: Relapsing Remitting Multiple Sclerosis
    View official trial listing →
  • Not yet recruiting NCT NCT07483632

    A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

    Not yet reported Biogen 185 participants Est. completion 2035-06-19 Stand-alone
    Other conditions: Relapsing Forms of Multiple Sclerosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Fingolimod Hydrochloride, Fingolimod

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.